Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$13.81 - $19.33 $1,974 - $2,764
143 Added 1.06%
13,664 $204,000
Q4 2023

Feb 13, 2024

BUY
$10.87 - $15.93 $40,827 - $59,833
3,756 Added 38.46%
13,521 $202,000
Q3 2023

Nov 13, 2023

BUY
$8.84 - $22.64 $3,076 - $7,878
348 Added 3.7%
9,765 $136,000
Q2 2023

Aug 04, 2023

BUY
$8.75 - $14.29 $82,398 - $134,568
9,417 New
9,417 $97,000
Q2 2022

Aug 12, 2022

SELL
$5.12 - $8.74 $49,587 - $84,646
-9,685 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$5.92 - $9.73 $4,037 - $6,635
-682 Reduced 6.58%
9,685 $84,000
Q4 2021

Feb 11, 2022

SELL
$9.03 - $19.13 $2,790 - $5,911
-309 Reduced 2.89%
10,367 $99,000
Q3 2021

Nov 12, 2021

SELL
$14.31 - $18.39 $3,634 - $4,671
-254 Reduced 2.32%
10,676 $180,000
Q2 2021

Aug 13, 2021

SELL
$15.2 - $20.94 $5,563 - $7,664
-366 Reduced 3.24%
10,930 $167,000
Q1 2021

May 07, 2021

BUY
$17.99 - $26.96 $521 - $781
29 Added 0.26%
11,296 $220,000
Q4 2020

Feb 12, 2021

SELL
$17.54 - $25.43 $5,682 - $8,239
-324 Reduced 2.8%
11,267 $203,000
Q3 2020

Nov 04, 2020

SELL
$18.81 - $26.42 $4,928 - $6,922
-262 Reduced 2.21%
11,591 $224,000
Q2 2020

Aug 12, 2020

BUY
$16.5 - $29.7 $12,573 - $22,631
762 Added 6.87%
11,853 $310,000
Q1 2020

May 04, 2020

SELL
$13.68 - $34.6 $8,782 - $22,213
-642 Reduced 5.47%
11,091 $198,000
Q4 2019

Feb 05, 2020

SELL
$21.11 - $34.86 $2,068 - $3,416
-98 Reduced 0.83%
11,733 $392,000
Q3 2019

Nov 08, 2019

SELL
$23.83 - $36.44 $1,954 - $2,988
-82 Reduced 0.69%
11,831 $282,000
Q2 2019

Aug 23, 2019

BUY
$32.75 - $40.35 $390,150 - $480,689
11,913 New
11,913 $428,000

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $289M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.